Ariad Pharma (Nasdaq: ARIA) shares are being pressured Friday following an update from management over its pending cancer drug ponatinib.
This article: 115 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE